Patenting stem cells and genes in Europe


By Wolfgang Weiss and Christian Heubeck, Weickmann & Weickmann. This article first appeared in IAM Life Sciences 2017, a supplement to IAM, published by Globe Business Media Group - IP Division.



2016年6月24日と 2016年年9月26日の私どものニュースのアップデート

EPO: Improved refund system for the examination fee after withdrawal of an application


Obviously as incentive for a withdrawal of applications with low chances of success and/or minor commercial value by the applicants and thus reducing the heavy workload of the EPO, new...

Unitary Patent Protection in Europe on its way and then … Brexit


By Michael Dey Ph.D., Frank Feller Ph.D., Weickmann & Weickmann PartmbB and John McDonald Ph.D., J.D., Kilpatrick Townsend & Stockton LLP

Key issues in building a strong life sciences patent portfolio


Innovator companies in the life sciences field need to protect their technology, which often involves development projects for new medicaments.

Community Trademark, Community Design and Unitary Patent – Brexit raises questions over questions


On June 23, 2016, the British people decided to leave the European Union. This historic decision not only puts the fate of the Unitary Patent System at stake, but also raises questions with respect to the validity of existing...

Displaying results 29 to 35 out of 47